FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W88262059> ?p ?o ?g. }

• W88262059 endingPage "1141" @default.
• W88262059 startingPage "1138" @default.
• W88262059 abstract "No AccessJournal of Urology1 Jun 1990Intracavernous Injection Therapy: Analysis of Results and Complications Milton M. Lakin, Drogo K. Montague, Sharon Vanderbrug Medendorp, Linda Tesar, and Leslie R. Schover Milton M. LakinMilton M. Lakin More articles by this author , Drogo K. MontagueDrogo K. Montague More articles by this author , Sharon Vanderbrug MedendorpSharon Vanderbrug Medendorp More articles by this author , Linda TesarLinda Tesar More articles by this author , and Leslie R. SchoverLeslie R. Schover More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)40208-4AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Experience with 100 patients who used intracavernous injection therapy with a combination of papaverine with or without phentolamine for 29 months is analyzed in detail. The largest group of patients had vasculogenic erectile failure (56%). At the end of followup 50% of the patients were no longer performing injection. Those who discontinued injection therapy were slightly older and had more vasculogenic erectile failure. The nonfibrotic complications were mild in all instances and did not result in discontinuation of injection therapy. These complications consisted of small hematomas in 20.9% of the patients, mild discomfort in 13.6% and mild liver enzyme abnormalities in 9.8%. No episode of priapism or infection occurred during therapy. Fibrotic complications consisted of nodules or plaques, and correlated significantly with the number of months on injection and the number of injections. At 12 months the fibrotic complication rate was 31 ± 8.6%. Our study suggests caution regarding the long-term complication rate of intracavernous injection therapy with these compounds and underscores the importance of routine followup examinations. While injection therapy is an effective form of treatment for erectile failure, it is not a satisfactory alternative for many patients and is associated with a significant fibrotic complication rate. © 1990 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByBurnett A, Nehra A, Breau R, Culkin D, Faraday M, Hakim L, Heidelbaugh J, Khera M, McVary K, Miner M, Nelson C, Sadeghi-Nejad H, Seftel A and Shindel A (2018) Erectile Dysfunction: AUA GuidelineJournal of Urology, VOL. 200, NO. 3, (633-641), Online publication date: 1-Sep-2018.NALESNIK J, JONES L and KRAUS S (2018) GROUP B STREPTOCOCCAL SEPTICEMIA FOLLOWING INTRACAVERNOUS INJECTION THERAPY FOR ERECTILE DYSFUNCTION IN DIABETESJournal of Urology, VOL. 172, NO. 1, (151-152), Online publication date: 1-Jul-2004.WESPES E, SATTAR A, NOËL J and SCHULMAN C (2018) DOES PROSTAGLANDIN E1 THERAPY MODIFY THE INTRACAVERNOUS MUSCULATURE?Journal of Urology, VOL. 163, NO. 2, (464-466), Online publication date: 1-Feb-2000.BIVALACQUA T, CHAMPION H, RAJASEKARAN M, SIKKA S, KADOWITZ P, DOHERTY P and HELLSTROM W (2018) POTENTIATION OF ERECTILE RESPONSE AND cAMP ACCUMULATION BY COMBINATION OF PROSTAGLANDIN E1 AND ROLIPRAM, A SELECTIVE INHIBITOR OF THE TYPE 4 PHOSPHODIESTERASE (PDE 4)Journal of Urology, VOL. 162, NO. 5, (1848-1855), Online publication date: 1-Nov-1999.CHAMPION H, BIVALACQUA T, WANG R, KADOWITZ P, KEEFER L, SAAVEDRA J, HRABIE J, DOHERTY P and HELLSTROM W (2018) INDUCTION OF PENILE ERECTION BY INTRACAVERNOSAL AND TRANSURETHRAL ADMINISTRATION OF NOVEL NITRIC OXIDE DONORS IN THE CATJournal of Urology, VOL. 161, NO. 6, (2013-2019), Online publication date: 1-Jun-1999.FAZELI-MATIN S, MONTAGUE D, ANGERMEIER K and LAKIN M (2018) PENILE FRACTURE AFTER INTRACAVERNOUS INJECTION THERAPYJournal of Urology, VOL. 159, NO. 6, (2094-2094), Online publication date: 1-Jun-1998.Bechara A, Casabe A, Cheliz G, Romano S, Rey H and Fredotovich N (2018) Comparative Study of Papaverine Plus Phentolamine Versus Prostaglandin E1 in Erectile DysfunctionJournal of Urology, VOL. 157, NO. 6, (2132-2134), Online publication date: 1-Jun-1997.Godschalk M, Gheorghiu D, Katz G and Mulligan T (2018) Alkalization Does Not Alleviate Penile Pain Induced By Intracavernous Injection of Prostaglandin E1Journal of Urology, VOL. 156, NO. 3, (999-1000), Online publication date: 1-Sep-1996.Porst H (2018) The Rationale for Prostaglandin E1 in Erectile Failure: A Survey of Worldwide ExperienceJournal of Urology, VOL. 155, NO. 3, (802-815), Online publication date: 1-Mar-1996.Bechara A, Casabe A, Cheliz G, Romano S and Fredotovich N (2018) Prostaglandin E1 Versus Mixture of Prostaglandin E1, Papaverine and Phentolamine in Nonresponders to High Papaverine Plus Phentolamine DosesJournal of Urology, VOL. 155, NO. 3, (913-914), Online publication date: 1-Mar-1996.Chen R, Lakin M, Montague D and Ausmundson S (2018) Penile Scarring with Intracavernous Injection Therapy Using Prostaglandin E1: A Risk Factor AnalysisJournal of Urology, VOL. 155, NO. 1, (138-140), Online publication date: 1-Jan-1996.Shenfeld O, Hanani J, Shalhav A, Vardi Y and Goldwasser B (2018) Papaverine-Phentolamine and Prostaglandin E1 Versus Papaverine-Phentolamine Alone For Intracorporeal Injection Therapy: A Clinical Double-Blind StudyJournal of Urology, VOL. 154, NO. 3, (1017-1019), Online publication date: 1-Sep-1995.Chen J, Godschalk M, Katz P and Mulligan T (2018) Incidence of Penile Pain After Injection of a New Formulation of Prostaglandin E1Journal of Urology, VOL. 154, NO. 1, (77-79), Online publication date: 1-Jul-1995.Kim E and McVary K (2018) Topical Prostaglandin-E1 for the Treatment of Erectile DysfunctionJournal of Urology, VOL. 153, NO. 6, (1828-1830), Online publication date: 1-Jun-1995.Kim E, El-Rashidy R and McVary K (2018) Papaverine Topical Gel for Treatment of Erectile DysfunctionJournal of Urology, VOL. 153, NO. 2, (361-365), Online publication date: 1-Feb-1995.Chen J, Godschalk M, Katz P and Mulligan T (2018) Peyronie’s-Like Plaque after Penile Injection of Prostaglandin E1Journal of Urology, VOL. 152, NO. 3, (961-962), Online publication date: 1-Sep-1994.Kerfoot W, Young Park H, Schwartz L, Hagen P and Carson C (2018) Characterization of Calcium Channel Blocker Induced Smooth Muscle Relaxation Using a Model of Isolated Corpus CavernosumJournal of Urology, VOL. 150, NO. 1, (249-252), Online publication date: 1-Jul-1993.Porst H (2018) Prostaglandin E1 and the Nitric Oxide Donor Linsidomine for Erectile Failure: A Diagnostic Comparative Study of 40 PatientsJournal of Urology, VOL. 149, NO. 5 Part 2, (1280-1283), Online publication date: 1-May-1993.Moriel E and Raifer J (2018) Sodium Bicarbonate Alleviates Penile Pain Induced by Intracavernous Injections for Erectile DysfunctionJournal of Urology, VOL. 149, NO. 5 Part 2, (1299-1300), Online publication date: 1-May-1993.Beer S and See W (2018) Intracorporeal Needle Breakage: An Unusual Complication of Papaverine Injection Therapy for ImpotenceJournal of Urology, VOL. 147, NO. 1, (148-150), Online publication date: 1-Jan-1992.Nicely E, Costabile R and Moul J (2018) Rupture of the Deep Dorsal Vein of the Penis During Sexual IntercourseJournal of Urology, VOL. 147, NO. 1, (150-152), Online publication date: 1-Jan-1992.Gerstenberg T, Metz P, Ottesen B and Fahrenkrug J (2018) Intracavernous Self-Injection with Vasoactive Intestinal Polypeptide and Phentolamine in the Management of Erectile FailureJournal of Urology, VOL. 147, NO. 5, (1277-1279), Online publication date: 1-May-1992.Gerber G and Levine L (2018) Pharmacological Erection Program Using Prostaglandin E1Journal of Urology, VOL. 146, NO. 3, (786-789), Online publication date: 1-Sep-1991.Kerfoot W and Carson C (2018) Pharmacologically Induced Erections Among Geriatric MenJournal of Urology, VOL. 146, NO. 4, (1022-1024), Online publication date: 1-Oct-1991.Benson G (2018) Editorial CommentsJournal of Urology, VOL. 145, NO. 2, (293-293), Online publication date: 1-Feb-1991. Volume 143Issue 6June 1990Page: 1138-1141 Advertisement Copyright & Permissions© 1990 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Milton M. Lakin More articles by this author Drogo K. Montague More articles by this author Sharon Vanderbrug Medendorp More articles by this author Linda Tesar More articles by this author Leslie R. Schover More articles by this author Expand All Advertisement Loading ..." @default.
• W88262059 created "2016-06-24" @default.
• W88262059 creator A5000677955 @default.
• W88262059 creator A5039497943 @default.
• W88262059 creator A5043883395 @default.
• W88262059 creator A5061104153 @default.
• W88262059 creator A5074034525 @default.
• W88262059 date "1990-06-01" @default.
• W88262059 modified "2023-10-14" @default.
• W88262059 title "Intracavernous Injection Therapy: Analysis of Results and Complications" @default.
• W88262059 cites W108175115 @default.
• W88262059 cites W172453015 @default.
• W88262059 cites W181735378 @default.
• W88262059 cites W1978270940 @default.
• W88262059 cites W1987546609 @default.
• W88262059 cites W1993652492 @default.
• W88262059 cites W2012712025 @default.
• W88262059 cites W2023223049 @default.
• W88262059 cites W2126172182 @default.
• W88262059 cites W2417893760 @default.
• W88262059 cites W24186431 @default.
• W88262059 cites W2428149043 @default.
• W88262059 cites W4252684946 @default.
• W88262059 cites W4293241248 @default.
• W88262059 cites W62347871 @default.
• W88262059 cites W73647713 @default.
• W88262059 doi "https://doi.org/10.1016/s0022-5347(17)40208-4" @default.
• W88262059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2342174" @default.
• W88262059 hasPublicationYear "1990" @default.
• W88262059 type Work @default.
• W88262059 sameAs 88262059 @default.
• W88262059 citedByCount "161" @default.
• W88262059 countsByYear W882620592012 @default.
• W88262059 countsByYear W882620592013 @default.
• W88262059 countsByYear W882620592014 @default.
• W88262059 countsByYear W882620592015 @default.
• W88262059 countsByYear W882620592016 @default.
• W88262059 countsByYear W882620592017 @default.
• W88262059 countsByYear W882620592018 @default.
• W88262059 countsByYear W882620592019 @default.
• W88262059 countsByYear W882620592020 @default.
• W88262059 countsByYear W882620592022 @default.
• W88262059 crossrefType "journal-article" @default.
• W88262059 hasAuthorship W88262059A5000677955 @default.
• W88262059 hasAuthorship W88262059A5039497943 @default.
• W88262059 hasAuthorship W88262059A5043883395 @default.
• W88262059 hasAuthorship W88262059A5061104153 @default.
• W88262059 hasAuthorship W88262059A5074034525 @default.
• W88262059 hasConcept C141071460 @default.
• W88262059 hasConcept C71924100 @default.
• W88262059 hasConceptScore W88262059C141071460 @default.
• W88262059 hasConceptScore W88262059C71924100 @default.
• W88262059 hasIssue "6" @default.
• W88262059 hasLocation W882620591 @default.
• W88262059 hasLocation W882620592 @default.
• W88262059 hasOpenAccess W88262059 @default.
• W88262059 hasPrimaryLocation W882620591 @default.
• W88262059 hasRelatedWork W1586374228 @default.
• W88262059 hasRelatedWork W2003938723 @default.
• W88262059 hasRelatedWork W2047967234 @default.
• W88262059 hasRelatedWork W2089201504 @default.
• W88262059 hasRelatedWork W2118496982 @default.
• W88262059 hasRelatedWork W2364998975 @default.
• W88262059 hasRelatedWork W2369162477 @default.
• W88262059 hasRelatedWork W2439875401 @default.
• W88262059 hasRelatedWork W4238867864 @default.
• W88262059 hasRelatedWork W2525756941 @default.
• W88262059 hasVolume "143" @default.
• W88262059 isParatext "false" @default.
• W88262059 isRetracted "false" @default.
• W88262059 magId "88262059" @default.
• W88262059 workType "article" @default.